Cross-Sectional Analysis of Washington State Prior Authorization Response Times 2022-2024 (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1718; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "These included adalimumab (3 carriers), etanercept (1 carrier), secukinumab (1 carrier), risankizumab (4 carriers), and upadacitinib (1 carrier). Publicly reported prior authorization metrics for rheumatologic therapies in Washington State include high approval rates and short response times, with adalimumab being the most prescribed biologic. However, substantial variability across carriers highlight the limitations in the reporting framework. The presence of extremely rapid determinations suggest potential automation."
|
|
Renato Ferrandiz Espadin; Londyn Robinson; jenna Thomason; Dominique Feterman; Alison Bays
|